Yaping Chang

Jilin University, Yung-chi, Jilin Sheng, China

Are you Yaping Chang?

Claim your profile

Publications (2)4.74 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Two efficient pH-responsive oral delivery systems have been fabricated through a dative bonding between the amino-functionalized mesoporous silica materials, including MCM-41-type mesoporous silica nanospheres (MMSNs) and bimodal mesoporous silica microspheres (BMSMs), and an antitumour-active polyoxometalate K(8)H(2)[Ti(H(2)O)](3)SiW(9)O(34) (Ti(3)SiW(9)). The Ti(3)SiW(9) loaded in the pores of MMSNs and BMSMs are up to 23.72 wt% and 28.69 wt% at pH 6.5, respectively. Both delivery systems reveal an increase of Ti(3)SiW(9) release under mildly alkaline conditions, while zero premature release is observed under acidic and neutral conditions, making them ideal for use as a new class of colon-specific oral delivery systems. Importantly, these systems provide very promising possibilities for many medical applications that require an increase or decrease in the rate of drug release, depending on disease evolution. Upon incorporation into mesoporous silica materials, the antitumour activity of Ti(3)SiW(9) against Ls-174-T was improved from 0.8 mg mL(-1) to 0.186 and 0.102 mg mL(-1) for Ti(3)SiW(9)@MMSN-NH(2) and Ti(3)SiW(9)@BMSM-NH(2), respectively.
    Dalton Transactions 07/2009; · 3.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polymorphisms in DNA repair genes are good candidates for modifying cancer risk. ERCC2/XPD, a gene involved in nucleotide excision repair and basal transcription, may influence individual DNA repair capacity, particularly of bulky adducts. This is implicated in cancer susceptibility. To detect the association between ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population, we conducted a hospital-based case-control study consisting of 129 patients with breast cancer and 205 controls matched by age, gender, and ethnicity. PCR-RFLP was used for genotyping. No associations were found between ERCC2/XPD Arg156Arg and risk of breast cancer (AA/AC versus CC: OR = 0.79, 95% CI = 0.49-1.28, P = 0.33; AA versus CC: OR = 0.89, 95% CI = 0.49-1.63, P = 0.72; AC versus CC: OR = 0.74, 95% CI = 0.44-1.24, P = 0.25). Breast cancer cases with the variant AA genotype were marginally younger (mean age 45 years) than cases with the wild CC genotype (mean age 50 years) (P = 0.05). There were no differences in risk estimates in relation to menopause and occurrence of breast cancer. Our findings do not suggest that ERCC2/XPD Arg156Arg contributes to breast cancer susceptibility in a Chinese population.
    Biochemical Genetics 06/2009; 47(7-8):582-90. · 0.94 Impact Factor